{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Living+Alone&page=2",
    "query": {
      "condition": "Living Alone",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Living+Alone&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T05:35:06.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00615524",
      "title": "Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "exemestane and pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615524"
    },
    {
      "nct_id": "NCT03168438",
      "title": "Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Letetresgene autoleucel",
          "type": "DRUG"
        },
        {
          "name": "Letetresgene autoleucel with pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2017-08-18",
      "completion_date": "2020-11-05",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03168438"
    },
    {
      "nct_id": "NCT00019448",
      "title": "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma",
        "Recurrent Melanoma"
      ],
      "interventions": [
        {
          "name": "gp100 antigen",
          "type": "DRUG"
        },
        {
          "name": "interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-09",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019448"
    },
    {
      "nct_id": "NCT00382980",
      "title": "Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated Vero cell based whole virus influenza A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 308,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Torrance, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00382980"
    },
    {
      "nct_id": "NCT00002123",
      "title": "A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Delavirdine mesylate",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacia and Upjohn",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002123"
    },
    {
      "nct_id": "NCT03595059",
      "title": "A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ABBV-155",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2018-07-13",
      "completion_date": "2025-09-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03595059"
    },
    {
      "nct_id": "NCT02317926",
      "title": "Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypothyroidism"
      ],
      "interventions": [
        {
          "name": "Levothyroxine",
          "type": "DRUG"
        },
        {
          "name": "Levothyroxine Plus Liothyronine",
          "type": "DRUG"
        },
        {
          "name": "Desiccated Thyroid Extract",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed National Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 81,
      "start_date": "2015-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-05-06",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 1,
      "location_summary": "Besthesda, Maryland",
      "locations": [
        {
          "city": "Besthesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02317926"
    },
    {
      "nct_id": "NCT00151749",
      "title": "WelChol® and Insulin in Treating Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Colesevelam hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 260,
      "start_date": "2004-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2012-01-18",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 45,
      "location_summary": "Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more",
      "locations": [
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151749"
    },
    {
      "nct_id": "NCT03363776",
      "title": "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986277",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-12-06",
      "completion_date": "2019-11-22",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363776"
    },
    {
      "nct_id": "NCT02740270",
      "title": "Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphomas"
      ],
      "interventions": [
        {
          "name": "GWN323",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2016-07-22",
      "completion_date": "2020-03-03",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-06-11T05:35:06.704Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740270"
    }
  ]
}